ProNAi licenses oncology drug targeting DNA damage response Checkpoint kinase 1 (Chk1) from CRT Pioneer Fund, UK 28 Sep 2016 ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced that it has obtained an exclusive license from the CRT Pioneer Fund LP for worldwide rights to develop and commercialize PNT737 (formerly CCT245737), a highly selective, orally available, small molecule inhibitor of Checkpoint kinase 1 (Chk1). Find out more Show/Hide